Hematology and Oncology Studies

Utilize PPD’s experience and effective management of oncology drug development from preclinical through Phase I-IV studies. With a dedicated hematology/oncology team led by senior scientists and clinicians, PPD expedites development timelines for emerging therapies by offering:

• A global infrastructure
• Full development services from preclinical through post-approval
• Multinational regulatory expertise

Established and Experienced

Our hematology and oncology team consists of more than 500 professionals across the globe. Our senior medical director of hematology/oncology, Dr. J. Kyle Bryan, is board certified in internal medicine, hematology and medical oncology. With more than a decade of drug discovery and development experience in the pharmaceutical and biotech industry, Dr. Bryan provides critical scientific oversight and leadership.

In addition, our international oncology advisory board provides clinical insight and drug development consulting for PPD clients.

Global Investigator Network

PPD has a global network of more than 3,800 investigators with experience in hematology and oncology clinical research. We maintain close relationships and consulting agreements with physicians at most of the major tertiary and academic cancer treatment centers. Over the past five years, PPD has conducted more than 270 hematology/oncology trials at major cancer institutions worldwide.

Full Development Services

PPD provides development-focused therapeutic specialists from preclinical investigation through post-approval reporting:

• Piedmont Research Center, delivering:
• Preclinical research and evaluation of anticancer therapies
• Strategic study design consulting
• High quality in vivo and in vitro laboratory testing, including murine and xenograft models
• Preclinical schedule optimization
• Combination, pharmacokinetic and pharmacodynamic studies
• Mechanism and biomarker elucidation and validation
• Investigator-initiated research protocols in oncology conducted in large cancer centers and local community practices, including IND exempt and non-exempt trials:
• Non-small cell lung cancer
• Prostate cancer
• Breast cancer
• Ovarian cancer
• Therapeutic safety profiles focused on specific cellular targets, enhancing the likelihood of accelerated access to the market
• Post-approval capabilities, including:
• Late stage trials
• Consumer health
• Online marketing and education
• Medical communications